Indication:Treatment of anemia due to:• Chronic Kidney Disease (CKD) in patients on dialysis and patients not on dialysis• The effects of concomitant myelosuppressive chemotherapy, and upon initiation, there is a minimum of two additional months of planned chemotherapy

Dosage & Administration:

Recommended starting dose for patients with CKD on dialysis • 0.45 mcg/kg intravenously or subcutaneously weekly or • 0.75 mcg/kg intravenously or subcutaneously every 2 weeks • Intravenous route is recommended for patients on hemodialysis Recommended starting dose for patients with CKD not on dialysis • 0.45 mcg/kg intravenously or subcutaneously at 1 month interval Recommended starting dose for pediatric patients with CKD • 0.45 mcg/kg intravenously or subcutaneously weekly • Patients with CKD not on dialysis may also be initiated at 0.75 mcg/kg every 2 weeks Recommended starting dose for patients with cancer on chemotherapy • 2.25 mcg/kg subcutaneously wShow more 

Preparation:DarborenTM Pre-filled Syringe: Each box contains 1 Pre-filled syringe containing 25 mcg of Darbepoetin alfa in Alu-PVC blister pack.DarborenTM Pre-filled Syringe: Each box contains 1 Pre-filled syringe containing 40 mcg of Darbepoetin alfa in Alu-PVC blister pack.DarborenTM 60 Pre-filled Syringe: Each box contains 1 Pre-filled syringe containing 60 mcg of Darbepoetin alfa in Alu-PVC blister pack.